Wuhan Cadvis Biotechnology
The medical laboratory focuses on the research and application of high-end medical inspection technology in the field of gynecological tumor diagnosis and treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY200m | Series B | |
| Total Funding | 000k | ||
Related Content
Wuhan Cadvis Biotechnology Co., Ltd. is a national-level, specialized, and new "little giant" enterprise focused on women's and children's health, as well as tumor gene diagnosis and gene therapy. The company was established in February 2018. It was jointly created with the Tongji Hospital, which is affiliated with the Tongji Medical College of Huazhong University of Science and Technology, and the team of academician Martin Ma of the Chinese Academy of Engineering.
The company's core mission is to address clinical needs by developing diagnostic reagents, innovative biological drugs, medical devices, and new technologies, in addition to providing related services. Its operations span the entire healthcare cycle, including prevention, screening, diagnosis, monitoring, and treatment. The business model integrates research and development, incubation, transformation, service, and production. Revenue is generated through a combination of product sales, clinical testing services, and technology output. The company's primary clients are major hospitals, with its products and services having been implemented in nearly 50 top-tier hospitals across China.
A key figure behind the company is its chief scientist, Martin Ma, an academician of the Chinese Academy of Engineering and director of the Department of Obstetrics and Gynecology at Tongji Hospital. With a Ph.D. from Tongji Medical University and postdoctoral research experience at the University of Texas Southwestern Medical Center, his extensive background and numerous patents in gynecological oncology have been foundational to the company's direction. His leadership has been instrumental in translating scientific research into clinical applications.
Wuhan Cadvis Biotechnology offers a range of products, including the CerviPer® HPV integration detection kit, which provides precise screening for cervical diseases by accurately genotyping high-risk HPV types. Another significant product is the EcPredict® endometrial cancer non-invasive early screening kit, which received market approval. Furthermore, the company is developing a pipeline of over 10 oncolytic adenovirus injection products designed to revolutionize tumor gene therapy and activate anti-tumor immunity. Through its subsidiary, Wuhan Cadvis Medical Laboratory Co., Ltd., the company also offers high-end medical testing services, specializing in next-generation sequencing (NGS) for gynecological tumor diagnosis and treatment.
Keywords: gynecological oncology, gene diagnosis, gene therapy, diagnostic reagents, HPV testing, endometrial cancer screening, oncolytic virus, next-generation sequencing, clinical translation, medical devices, biopharmaceuticals, women's health, tumor screening, Martin Ma, molecular diagnostics, precision medicine, cancer detection, biotechnology, clinical research, medical testing